Comparative Pharmacology
Head-to-head clinical analysis: MANGANESE SULFATE versus MVC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANGANESE SULFATE versus MVC PLUS.
MANGANESE SULFATE vs MVC PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Manganese sulfate is a source of manganese, a trace element that acts as a cofactor for various enzymes including arginase, pyruvate carboxylase, and superoxide dismutase. It is essential for normal bone formation, blood clotting, and nervous system function.
MVC PLUS is a fixed-dose combination of maraviroc, a CCR5 co-receptor antagonist, and lamivudine, a nucleoside reverse transcriptase inhibitor. Maraviroc binds to CCR5 on CD4+ T cells blocking HIV-1 entry; lamivudine inhibits HIV reverse transcriptase via competitive inhibition and chain termination.
Intravenous: 0.1-0.2 mg manganese/kg/day (as manganese sulfate) added to TPN. Maximum 0.15-0.8 mg/day. Injection IV: 0.1-0.2 mg manganese/kg/day.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life approximately 37 days (range 30–45 days) in whole body; reflects slow turnover in tissues, especially bone and liver. Clinical context: Accumulation occurs with chronic high exposure or impaired biliary excretion (e.g., hepatic disease).
Terminal elimination half-life: 12-18 hours (mean 14 hours). Clinically, this supports twice-daily dosing with steady-state achieved in ~3 days.
Primarily fecal (biliary) elimination of unabsorbed manganese; absorbed manganese is excreted mainly in bile (99%) with minimal renal excretion (<1%). Small amounts secreted in pancreatic juice and reabsorbed enterally.
Renal: ~70% unchanged; Fecal: ~25%; Biliary: <5%
Category C
Category C
Mineral Supplement
Multivitamin/Mineral Supplement